Benzeneacetic acid, 4-[[[[[2,6-dichloro-2'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]amino]carbonyl]amino]methyl]-

Biological Activity

RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved drug-like properties, with an IC50 of 63.8 nM[1]. RORγt inverse agonist 13 (Compound 3i) exhibits activity with an inhibition of 76% at 0.3 μM in Th17 cell differentiation assay[1]. RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model[1].

References

[1]. Nannan Sun, et al. Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists. Eur J Med Chem. 2020 Jul 5;202:112536.